Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Anti-BCMA CAR-T cells
BIOLOGICAL
2 trials
Sponsors
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
, Hrain Biotechnology Co., Ltd.
Conditions
Multiple Myeloma
Early Phase 1
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
NCT03943472
Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Start: 2019-07-08
End: 2022-05-31
Target: 10
Updated: 2021-08-31
Phase 1
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
NCT03093168
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Multiple Myeloma
Start: 2017-02-15
End: 2020-02-29
Target: 10
Updated: 2019-02-27
Related Papers
Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study
Blood
2019-11-13
33 citations
Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients.
Journal of Clinical Oncology
2019-05-20
Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma
Blood
2018-11-29
35 citations
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
Journal of Clinical Oncology
2018-05-20
9 citations